In September 2015, Rigel entered into an exclusive, worldwide licensing agreement with Aclaris Therapeutics for rights to develop and commercialize certain Janus tyrosine kinase (JAK) inhibitors that were discovered in Rigel’s laboratories.
The agreement covers the investigational compounds now referred to as ATI-501 (oral) and ATI-502 (topical), in alopecia areata (AA) and other specified dermatological conditions, including androgenetic alopecia (AGA), vitiligo, and atopic dermatitis.
Rigel received an upfront payment and is eligible to receive various milestone payments based on global development in multiple indications, as well as tiered royalties on any future net sales of commercialized products.
Development of AT-501:
- Completed Phase 2 evaluating three dose levels in patients with AA
Development of ATI-502:
- Ongoing Phase 2 in the regrowth of hair in AGA patients
- 12-month data expected in the 4Q 2019
- Completed Phase 2 clinical trial in adult patients with moderate-to-severe atopic dermatitis